In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a placebo.
The next big obesity medication coming down the pipeline will likely come in pill form. Eli Lilly has just released the latest positive Phase III trial results of its experimental oral GLP-1 drug, orforglipron.
On Tuesday morning, Eli Lilly reported that orforglipron met the benchmarks of the company’s Phase III ATTAIN-2 study. People taking orforglipron experienced substantial improvements in weight loss and blood sugar control compared to those taking a placebo, the study showed. Armed with data from two successful Phase III trials, the company plans to apply for approval from the Food and Drug Administration, with a decision on the drug expected next year.The newest kid on the block
The ATTAIN-2 trial was conducted across 10 countries and involved more than 1,600 people who were obese or overweight with type 2 diabetes. Volunteers were randomized to either receive a placebo or one of three varying doses of orforglipron, taken once a day (as is common with GLP-1 therapy, people gradually reached their maximum dose over time). The participants were tracked for 72 weeks.
No matter the dose, people on orforglipron lost more weight and saw a greater reduction in blood sugar than people on placebo, the study found.
Those taking more of the drug did show more improvement, though. People on the highest dose of orforglipron lost on average around 10% of their baseline body weight, for instance, compared to the 2.
